Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
6
Neutral
3
Bullish
5
Bearish
7
Neutral
3
Bullish
36
Bearish
1
Neutral
0
Bullish
31
Bearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
5
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Bearish
1
Neutral
0
Bullish
31
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Samrat Pharmachem Limited, established in 1992, primarily manufactures and sells chemicals.
A key development was the creation of a subsidiary, Samrat Remedies Limited, focusing on pharmaceutical bulk drugs and chemicals.
The company leverages its long-standing experience in chemical manufacturing to expand into pharmaceuticals, a strategic move for diversification.
Their operational strategy includes advancing their pharmaceutical segment, aiming to capture a larger market share in the industry.
Pharmaceuticals & Biotechnology
Pharmaceuticals
86 Cr
Low Risk
-38.8
34.8
—
1.3
309.85
190.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6.87 | 93 Cr | 21.88 | 1.19 | 0.00 | 6.03 | 8.35 | 3.45 | ||
44.99 | 90 Cr | 8.02 | 1.12 | 1.11 | 13.48 | 18.36 | 12.76 | ||
68.06 | 90 Cr | 43.74 | 1.92 | 0.00 | 2.17 | 5.12 | 2.74 | ||
731.05 | 88 Cr | 21.04 | 1.51 | 0.48 | 8.32 | 10.75 | 5.27 | ||
277.50 | 86 Cr | -38.80 | 1.26 | 0.00 | -4.86 | -2.57 | -1.78 | ||
60.00 | 83 Cr | 10.43 | 0.91 | 4.17 | 9.18 | 13.14 | 6.39 | ||
50.95 | 78 Cr | 40.26 | 2.74 | 0.00 | 6.80 | 10.18 | 5.52 | ||
| Median: 7 Co. | — | 60.00 | 88 Cr | 21.04 | 1.26 | 0.00 | 6.80 | 10.18 | 5.27 |
Upcoming Result Date: Nov 13, 2026
Samrat Pharmachem Ltd (SAMRATPH) is currently trading at 279.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Samrat Pharmachem Limited, established in 1992, primarily manufactures and sells chemicals. A key development was the creation of a subsidiary, Samrat Remedies Limited, focusing on pharmaceutical bulk drugs and chemicals. The company leverages its long-standing experience in chemical manufacturing to expand into pharmaceuticals, a strategic move for diversification. Their operational strategy includes advancing their pharmaceutical segment, aiming to capture a larger market share in the industry.
Over the past 52 weeks, Samrat Pharmachem Ltd has traded between a low of ₹190.00 and a high of ₹309.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Samrat Pharmachem Ltd has a market capitalization of approximately 85.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Samrat Pharmachem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -38.80 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 85.74 Cr, Samrat Pharmachem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Samrat Pharmachem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Samrat Pharmachem Ltd is -38.80. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
